



MINDSET

An Alzheimer's Research Study

Aim

To investigate the safety and efficacy of RVT-101, a 5HT₆ receptor antagonist, when combined with stable doses of donepezil to promote regeneration of damaged brain cells in subjects with Alzheimer's disease (AD).

Phase III

Six-month double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate AD.

Hypothesis

AD is a progressive neurodegenerative disorder which affects cognitive processes. By combining current treatment (donepezil), which increases levels of acetylcholine, with a 5HT₆ receptor antagonist (RVT-101), which promotes neuro-regeneration, the AD process may be slowed.

Trial NCT02585934

Funding

- Axovant Sciences Limited
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the Mindset Study participants must:

- have mild to moderate AD,
- be 50-85 years of age,
- have a mini mental state exam score of 12-24,
- have a reliable caregiver (at least 10 hrs/week),
- have been taking donepezil (Aricept) for at least four months (stable dose of 5mg or 10mg for a minimum of two months).

Status

Currently enrolling

Ethics approval

Bellberry Human Research Ethics Committee
2016-01-002

Principal Investigator

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: projects@ndr.org.au